MA44227B1 - Anticorps pour il-17c - Google Patents

Anticorps pour il-17c

Info

Publication number
MA44227B1
MA44227B1 MA44227A MA44227A MA44227B1 MA 44227 B1 MA44227 B1 MA 44227B1 MA 44227 A MA44227 A MA 44227A MA 44227 A MA44227 A MA 44227A MA 44227 B1 MA44227 B1 MA 44227B1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
fragments
psoriasis
humans
Prior art date
Application number
MA44227A
Other languages
English (en)
Other versions
MA44227A (fr
Inventor
Jan Dominik Haas
Jürgen Klattig
Nick Ernest René Vandeghinste
Original Assignee
Galapagos Nv
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Morphosys Ag filed Critical Galapagos Nv
Publication of MA44227A publication Critical patent/MA44227A/fr
Publication of MA44227B1 publication Critical patent/MA44227B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps ou des fragments d'anticorps se liant à l'il-17c humaine. En particulier, l'invention concerne des anticorps ou des fragments d'anticorps qui présentent des propriétés bénéfiques combinées et sont donc utiles pour le traitement d'êtres humains présentant, par exemple, une dermatite atopique ou un psoriasis.
MA44227A 2016-02-19 2017-02-17 Anticorps pour il-17c MA44227B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Publications (2)

Publication Number Publication Date
MA44227A MA44227A (fr) 2018-12-26
MA44227B1 true MA44227B1 (fr) 2021-06-30

Family

ID=58057136

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43088A MA43088B1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c
MA44227A MA44227B1 (fr) 2016-02-19 2017-02-17 Anticorps pour il-17c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43088A MA43088B1 (fr) 2016-02-19 2017-02-17 Anticorps anti-il-17c

Country Status (32)

Country Link
US (4) US20190048071A1 (fr)
EP (1) EP3416983B1 (fr)
JP (2) JP6535139B2 (fr)
KR (1) KR102715157B1 (fr)
CN (1) CN108699143B (fr)
AU (1) AU2017219837B2 (fr)
BR (1) BR112018016798A2 (fr)
CA (1) CA3014842A1 (fr)
CL (1) CL2018002340A1 (fr)
CO (1) CO2018008724A2 (fr)
CU (1) CU20180087A7 (fr)
CY (1) CY1124296T1 (fr)
DK (1) DK3416983T3 (fr)
EA (1) EA037813B1 (fr)
EC (1) ECSP18070641A (fr)
ES (1) ES2877376T3 (fr)
HR (1) HRP20211059T1 (fr)
HU (1) HUE054755T2 (fr)
IL (1) IL260733B2 (fr)
LT (1) LT3416983T (fr)
MA (2) MA43088B1 (fr)
MD (1) MD3416983T2 (fr)
MX (1) MX2018009860A (fr)
PH (1) PH12018501739A1 (fr)
PL (1) PL3416983T3 (fr)
RS (1) RS62012B1 (fr)
SG (1) SG11201806161TA (fr)
SI (1) SI3416983T1 (fr)
TN (1) TN2018000289A1 (fr)
TW (1) TW201734041A (fr)
WO (1) WO2017140831A1 (fr)
ZA (1) ZA201806249B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359161A1 (fr) * 2015-10-05 2018-08-15 MorphoSys AG Antagonistes d'il-17c pour le traitement et/ou la prévention de la dermatite atopique
CU20180087A7 (es) 2016-02-19 2019-03-04 Galapagos Nv Anticuerpos para il-17-c
WO2019057982A1 (fr) 2017-09-25 2019-03-28 Morphosys Ag Traitement de la dermatite atopique
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (fr) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Sequences d'acides amines antigeniquement actives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1999060127A2 (fr) 1998-05-15 1999-11-25 Genentech, Inc. Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci
EP0985039B1 (fr) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Polypeptides d'anticorps artificiels
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
CA2467633C (fr) 2001-12-03 2012-03-27 Abgenix, Inc. Categorisation d'anticorps reposant sur des caracteristiques de liaison
BRPI0516603A (pt) 2004-10-18 2008-09-16 Zymogenetics Inc receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos para tratar uma doença imuno-mediada em um paciente em necessidade de tal tratamento, para reduzir a inflamação mediada pela il-17c, para tratar um mamìfero afligido com uma doença inflamatória, e para tratar uma condição patológica em um paciente associada com a atividade de zcytor21
WO2007047738A1 (fr) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Antagonistes de il-17c et méthodes d'utilisation desdits antagonistes
WO2008049070A2 (fr) 2006-10-18 2008-04-24 Zymogenetics, Inc. Antagonistes de l'il-17c et leurs procédés d'utilisation
EP3214442A1 (fr) * 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Traitement de l'inflammation gastro-intestinale, du psoriasis, de l'asthme, et du psoriasis a
RU2603080C2 (ru) 2010-11-19 2016-11-20 МорфоСис АГ Коллекция и способы ее применения
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
AU2012324895B2 (en) * 2011-10-19 2017-03-16 Galapagos Nv Antagonists of IL17C for the treatment of inflammatory disorders
WO2013186236A1 (fr) 2012-06-12 2013-12-19 Orega Biotech Antagonistes d'isoformes d'il-17 et leurs utilisations
DK3233915T3 (da) * 2014-12-15 2024-09-30 Morphosys Ag Antistoffer til il-17c
CU20180087A7 (es) 2016-02-19 2019-03-04 Galapagos Nv Anticuerpos para il-17-c

Also Published As

Publication number Publication date
CY1124296T1 (el) 2022-11-25
JP6916834B2 (ja) 2021-08-11
IL260733B1 (en) 2023-11-01
ES2877376T3 (es) 2021-11-16
US11987621B2 (en) 2024-05-21
MX2018009860A (es) 2019-03-28
CO2018008724A2 (es) 2018-08-31
AU2017219837A1 (en) 2018-08-09
BR112018016798A2 (pt) 2018-12-26
EP3416983A1 (fr) 2018-12-26
KR20180109977A (ko) 2018-10-08
MA44227A (fr) 2018-12-26
IL260733A (fr) 2018-09-20
EP3416983B1 (fr) 2021-04-07
IL260733B2 (en) 2024-03-01
KR102715157B1 (ko) 2024-10-10
US20190048071A1 (en) 2019-02-14
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
SI3416983T1 (sl) 2021-08-31
MA43088B1 (fr) 2020-10-28
JP6535139B2 (ja) 2019-06-26
ZA201806249B (en) 2020-02-26
EA201891594A1 (ru) 2019-01-31
PH12018501739A1 (en) 2019-06-10
RS62012B1 (sr) 2021-07-30
ECSP18070641A (es) 2018-10-31
JP2019162119A (ja) 2019-09-26
US20180340024A1 (en) 2018-11-29
US20200216529A1 (en) 2020-07-09
LT3416983T (lt) 2021-07-12
CA3014842A1 (fr) 2017-08-24
WO2017140831A1 (fr) 2017-08-24
SG11201806161TA (en) 2018-08-30
US10259869B2 (en) 2019-04-16
US10633439B2 (en) 2020-04-28
HRP20211059T1 (hr) 2021-10-01
HUE054755T2 (hu) 2021-09-28
MA43088A1 (fr) 2019-05-31
MD3416983T2 (ro) 2021-08-31
CL2018002340A1 (es) 2018-11-23
TN2018000289A1 (en) 2020-01-16
US20190202906A1 (en) 2019-07-04
EA037813B1 (ru) 2021-05-24
TW201734041A (zh) 2017-10-01
AU2017219837B2 (en) 2023-08-17
DK3416983T3 (en) 2021-06-21
PL3416983T3 (pl) 2021-10-25
CN108699143B (zh) 2021-11-09
JP2019511910A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
MA44227B1 (fr) Anticorps pour il-17c
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MY191649A (en) Antibodies to tigit
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MX2018014761A (es) Anticuerpos anti inmunoglobulina e (ige).
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EP4023674A3 (fr) Anticorps anti-il-22r
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
WO2022051591A3 (fr) Anticorps anti-nectine-4 et leurs utilisations
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201992688A1 (ru) Средства, пути применения и способы лечения
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
MX2022001604A (es) Anticuerpos anti bdca-2.
EA202192101A1 (ru) Соединения и их применение
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA202290061A1 (ru) Ингибиторы аутофагии на основе аминопиримидинамида и способы их применения